How Is AI Optimizing Different Aspects of FDA Submissions?

1. How Is AI Optimizing Different Aspects of FDA Submissions? • TheDepartmentofHealthandHumanServicesRegulatoryagencyisknownasTheFoodandDrug Administration. TheFDA is accountable for protecting and promotingpublichealththrough controlling and supervising food safety, tobacco products, dietary supplements, prescription and over-the-counterpharmaceutical drugs(medications),vaccines,biopharmaceuticals,blood transfusions, and medical devices. FDA approval is a must for any drug to be on the market. FDA playsacrucial roleinreviewingdrugs,medicaldevices,andbiologics beforeit entersthemarket. • The development of pharmaceuticalsis a complex and lengthy process. Companies abide by the regulatory body’s guidelines for the effectiveness of the drugs, vaccines, biologics, and medical devices, for which FDA submission is essential and crucial in several steps. Nowadays, companies areleveragingartificialintelligenceforeffectiveandquicksubmissions.TheFDAisalsodeveloping anewregulatory frameworkto promoteinnovation andsupportAI-based technologies. • ANew Strategyof the FDA in LeveragingAI: • In2017,theFDAannounceda‘DigitalHealthInnovationActionPlan’tooutlineitsstrategy toimplement usefulhealthcaretechnologies andpromoteAI-basedapplicationsin researchanddevelopment.Furthermore,theFDAisencouraginginitiativestodevelopand implement advanced predictive models in streamlining the drug review process. With an adequateregulatoryframework,safeandeffectivetherapiescanbediscovered,developed, andmarketedmuchfasterthan ever. • Traditionally, the FDA evaluates medical devices through a suitable premarket pathway, such as De Novo classification or premarket approval. The FDA may also analyze and clear modificationstomedicaldevices,includingsoftwareasamedicaldevice,dependingonthe importance of risk posed to patients by that modification. Learn the current FDA guidance for a risk-based approach for 510(k) software modifications. The FDA’s traditional medical deviceregulationparadigm wasnotintendedforadaptiveartificialintelligence and machinelearningtechnologies.UndertheFDA’scurrentapproachtosoftwarechanges,the FDA anticipates that many artificial intelligence and machine learning-driven software modificationstoa deviceneedapremarket review. • OnApril 2nd,2019, theFDAissued apaper,“ProposedRegulatoryFrameworkfor ModificationstoArtificialIntelligence/MachineLearning(AI/ML)-BasedSoftware asa Medical Device (SaMD) – Discussion Paper and Request for Feedback.” This explains the FDA’s foundation for a possible way to premarket review for artificial intelligence and machinelearning-drivensoftwaremodifications.

2. For more information, please visit @ https://www.iebrain.com/how-is-ai-optimizing-different- aspects-of-fda-submissions/ AboutIngenious e-BrainSolutions:- Ingenious e-BrainSolutionsprovideshigh-quality, customized, and cost-effectiveTechnology Intelligence,BusinessIntelligence, andIntellectualPropertyIntelligencesolutionstoindustry leaders,andinnovativecompaniesacrosstheglobe.Innovation,knowledge,andtransparencyform thebasisofourcompany’smissionandvision.Alongwithcostbenefits,weprovidehighestquality results ensuring fool-proof confidentiality and security. We are an ISO certified company with officesinIndia andUSA. Ingeniouse-BrainSolutionshasastrongteamofanalysts,andsubjectmatterexpertswithdomain proficiencywhichisdevotedtohelpclientsgrow.Ourhighlyqualifiedprofessionalsoffertailored, value-addedandcost-effectiveservicestoourclients.Webelieveinbuildinglongterm relationshipswithourclientswhoincludenationalandinternationalcorporations,Fortune500 companies, world’sleadingresearchinstitutesanduniversitiesaswellasindependentinventors. GetinTouch:- IndiaOffice 207-208 Welldone TechPark, Sohna Road Sector48,Gurugram,Haryana122018,India +911244294218 Email:- queries@iebrain.com